Effet protecteur des alpha-bloquants dans la Covid-19

INTRODUCTION: Research data suggests that alpha-1 adrenergic receptor antagonists may be effective in reducing mortality from hyper-inflammation. We set out to verify this hypothesis. Our study aimed to examine the link between the use of alpha blockers and reduction in the mortality linked to COVID-19 in a geriatric population at Paul Brousse Hospital. PATIENTS AND METHODS: This was a retrospective study of 193 male patients hospitalized for COVID-19 between March 2020 and March 2021. Two groups were formed according to exposure to an alpha-blocker. 61 patients were on alpha-blockers and 132 patients had no alpha-blocker in their usual treatment. RESULTS: The mortality rate was 29.5% in the first group and 33.33% in the group without alpha-blockers, with a p-value of 0.5967. We noted moderate symptomatology for 66 patients (34.2%), with 22 patients (36%) in the first group and 44 patients (33.3%) in the group without alpha-blocker. A severe clinical profile was observed for 73 patients (37.8%) including 20 (33%) in the group with alpha-blocker and 53 (40%) in the other group. CONCLUSION: We observed the absence of a reduction in the mortality rate in the group on alpha-blockers, and also the absence of excess mortality in this same group although they were more frail and at greater risk of dying. We therefore cannot exclude a beneficial effect of alpha-blockers in COVID-19.